Antineo: Acute Lymphoblastic Leukemia tumour model – RSA;11
-
RSA;11 cells
Human RS4;11 cells were isolated from the bone marrow a patient with Acute Lymphoblatic Leukemia.
-
Tumour growth in vivo
The cells were collected from a tissue culture flask and injected subcutaneously in the right flank of
SCID-CB17 mice. The resulting tumours were monitored by measuring two diameters with calipers,
and extrapolating the volume to a sphere.
The mice bearing RS4;11 tumours can be treated by intra-peritoneal, intra-venous, intra-tumoral or
subcutaneous injection of the compounds. Per os administration is also possible.
Figure 1: (View PDF)
Tumour growth curve of the RS4;11 cells as xenograft
Mean ± SEM (n=7; take rate 100%)
Antineo can also perform an IV implantation, using hCD45 Flow Cytometry as follow-up of tumour
progression.
-
Standard-Of-Care Drug Reponses
Rituximab, 30 mg/kg, bi-weekly → No Response
Figure 2: (View PDF)
Effect of rituximab or dexamethasone on RS4;11 tumour growth
Mean ± SEM (n=6 per group; take rate 100%)